ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
General Health & Fitness
Health Span Extension Research
Some good news from Japan at stem cell front.
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="Vince" data-source="post: 272219" data-attributes="member: 843"><p>In Japan, Kyoto University Hospital has been conducting an investigator-initiated clinical study since 2018 to confirm the safety and efficacy of the therapy by a research group led by Professor Jun Takahashi of CiRA. The researchers and physicians involved in the clinical study have exchanged information with UC San Diego's personnel involved in this clinical study.</p><p></p><p>In this clinical study, as with the clinical study at Kyoto University Hospital, Sumitomo Pharma will produce and provide iPS cell-derived dopaminergic progenitor cells. These cells will be produced in Japan from QHJI donor-derived iPS cells provided by the iPS Cell Stock Project of CiRA_F. Sumitomo Pharma will also provide financial support for the conduct of this clinical study. The data from this clinical study will be used for further development of the therapy in the United States.</p><p></p><p>In order to make technologies and know-how in the regenerative medicine/cell therapy area available to patients worldwide as soon as possible, Sumitomo Pharma, CiRA and CiRA_F are collaborating to commercialize this novel therapy. In addition to this clinical study, Sumitomo Pharma is preparing to initiate a company-sponsored clinical study outside Japan.</p><p></p><p>[URL unfurl="true"]https://www.cira.kyoto-u.ac.jp/e/pressrelease/news/231226-090000.html[/URL]</p></blockquote><p></p>
[QUOTE="Vince, post: 272219, member: 843"] In Japan, Kyoto University Hospital has been conducting an investigator-initiated clinical study since 2018 to confirm the safety and efficacy of the therapy by a research group led by Professor Jun Takahashi of CiRA. The researchers and physicians involved in the clinical study have exchanged information with UC San Diego's personnel involved in this clinical study. In this clinical study, as with the clinical study at Kyoto University Hospital, Sumitomo Pharma will produce and provide iPS cell-derived dopaminergic progenitor cells. These cells will be produced in Japan from QHJI donor-derived iPS cells provided by the iPS Cell Stock Project of CiRA_F. Sumitomo Pharma will also provide financial support for the conduct of this clinical study. The data from this clinical study will be used for further development of the therapy in the United States. In order to make technologies and know-how in the regenerative medicine/cell therapy area available to patients worldwide as soon as possible, Sumitomo Pharma, CiRA and CiRA_F are collaborating to commercialize this novel therapy. In addition to this clinical study, Sumitomo Pharma is preparing to initiate a company-sponsored clinical study outside Japan. [URL unfurl="true"]https://www.cira.kyoto-u.ac.jp/e/pressrelease/news/231226-090000.html[/URL] [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
X (Twitter)
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
General Health & Fitness
Health Span Extension Research
Some good news from Japan at stem cell front.
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top